A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00401479
Recruitment Status : Completed
First Posted : November 20, 2006
Last Update Posted : October 16, 2008
Information provided by:

Brief Summary:
This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time.

Condition or disease Intervention/treatment Phase
Irritable Bowel Syndrome (IBS) Drug: Placebo Drug: Solabegron (GW427353) Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Diagnostic
Official Title: An Exploratory Phase I Study in Healthy Volunteers of GI Transit Following Administration of the ß3-Adrenergic Receptor Agonist, Solabegron (Study B3I106248)
Study Start Date : October 2006

Intervention Details:
    Drug: Placebo Drug: Solabegron (GW427353)
    Other Name: Placebo

Primary Outcome Measures :
  1. colonic emptying rate by radiolabeled scintigraphy [ Time Frame: throughout the study ]

Secondary Outcome Measures :
  1. Safety and tolerability: ECG, vital signs, adverse events, clinical lab tests. Diary card collection of stool frequency Stool consistency and ease of passage Blood levels of GW427353 [ Time Frame: throughout the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects with no evidence of current or past history suggestive of gastrointestinal disease or disorder or medical illness that could compromise interpretation of the study.
  • no clinically significant laboratory results collected at the screening visit
  • men: body weight greater than or equal to 50kg (110 lbs)
  • women: body weight greater than or equal to 45kg (100 lbs)
  • BMI between 18.5 - 35 kg/m2

Exclusion Criteria:

  • Females who are nursing or pregnant.
  • history of inflammatory bowel disease
  • history of gastric ulcers within 12 months of signing the informed consent form
  • tobacco users

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00401479

United States, Minnesota
GSK Investigational Site
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Study Director: GSK Clinical Trials, MD GlaxoSmithKline

Responsible Party: Study Director, GSK Identifier: NCT00401479     History of Changes
Other Study ID Numbers: B3I106248
First Posted: November 20, 2006    Key Record Dates
Last Update Posted: October 16, 2008
Last Verified: October 2008

Keywords provided by GlaxoSmithKline:
b3-Adrenergic Receptor Agonist
Irritable Bowel Syndrome (IBS)
gastrointestinal transit

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Adrenergic Agonists
Adrenergic beta-3 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs